Prognostic factors and the impact of new therapies for CLL
Tuesday, January 19, 2016
The availability of new monoclonal antibodies and novel targeted therapies for chronic lymphocytic leukemia has greatly increased the complexity of treating symptomatic patients. Richard Furman, M.D. joins a panel of doctors and researchers in this OncLive video.
